Biomarkers of Heart Problems in People Using NSAIDs
Author Information
Author(s): Ricky Vaja, Plinio Ferreira, Laura Portas, Blerina Ahmetaj-Shala, Neringa Cypaite, Hime Gashaw, Jennifer Quint, Ramzi Khamis, Adam Hartley, Thomas M. MacDonald, Isla S. Mackenzie, Nicholas S. Kirkby, Jane A. Mitchell
Primary Institution: The National Heart and Lung Institute, Imperial College London
Hypothesis
What clinical risk factors and biomarkers are associated with cardiovascular events in NSAID users?
Conclusion
Growth differentiation factor 15 has been identified as a candidate biomarker for NSAID cardiovascular toxicity.
Supporting Evidence
- Clinical risk factors significantly associated with cardiovascular events included increasing age, male sex, smoking, total cholesterol:HDL ratio ≥5, and aspirin use.
- Statin use was found to be cardioprotective with an odds ratio of 0.68.
- Growth differentiation factor 15 was identified as a candidate biomarker with an area under the curve of 0.715.
Takeaway
This study looked at people taking painkillers called NSAIDs and found a new marker in the blood that might help predict heart problems.
Methodology
A post hoc analysis of the SCOT cohort was performed, identifying clinical risk factors and biomarkers associated with cardiovascular events.
Potential Biases
There may be unknown confounders not considered, and the study's exploratory nature does not imply causation.
Limitations
The study may not be generalizable as it was conducted in a low cardiovascular risk population and had a relatively small sample size for the case-control study.
Participant Demographics
Participants were NSAID users over 60 years old, with a majority being Caucasian.
Statistical Information
P-Value
0.0003
Confidence Interval
95% CI 0.63–0.81
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website